Asunaprevir (Standard)
Asunaprevir (Standard) is the analytical standard of Asunaprevir. This product is intended for research and analytical applications. Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM. Asunaprevir inhibits SARS-CoV-2 3CLpro activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 0%
- CAS No.: 630420-16-5
- Formule: C35H46ClN5O9S
- Masse moléculaire:748.29
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-14434
AsunaprevirHCV Protease Inhibitor -
HY-10237
BoceprevirHCV NS3 Protease Inhibitor -
HY-10235
TelaprevirHCV NS3-4A Protease Inhibitor -
HY-15298
GrazoprevirHCV Protease Inhibitor -
HY-10241
SimeprevirHCV NS3/4A Inhibitor -
HY-10238
DanoprevirHCV NS3/4A Inhibitor -
HY-10300
NarlaprevirNS3 Protease Inhibitor -
HY-15602
LedipasvirHCV NS5A Inhibitor -
HY-17634
GlecaprevirHCV NS3/4A Protease Inhibitor -
HY-12530
VelpatasvirHCV NS5A Inhibitor -
HY-10544
Tegobuvir -
HY-12594
ParitaprevirNS3/4A Protease Inhibitor
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 630420-16-5
-
Masse moléculaire 748.29
-
Formule C35H46ClN5O9S
-
SMILES
ClC1=CC=C2C(C(O[C@H]3CN(C([C@@H](NC(OC(C)(C)C)=O)C(C)(C)C)=O)[C@H](C(N[C@@]4(C(NS(C5CC5)(=O)=O)=O)[C@H](C=C)C4)=O)C3)=NC=C2OC)=C1
-
Synonyms
BMS-650032 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Pelosi LA, et al. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor BMS-790052. Antimicrob Agents Chemother. 2012 Jul 30. [Content Brief]
[2]. McPhee F, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012 Aug 6. [Content Brief]
[3]. McPhee F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012 Jul;56(7):3670-81. [Content Brief]
[4]. Pasquinelli C, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44. [Content Brief]
[5]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Asunaprevir (Standard) Related Classifications
HY-14434R Related Classifications
Powered by Bioz